CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
表达 CD20 特异性嵌合抗原受体的 T 细胞作为 rituximab 难治/复发 B 细胞非霍奇金淋巴瘤的挽救治疗
英文原题：CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma.
查看英文原题
CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
所有入组的既往对利妥昔单抗复发/难治的 B 细胞非霍奇金淋巴瘤患者均获得不同程度的临床缓解，且毒性可耐受。
中文摘要
背景与目的
输注靶向特定肿瘤相关抗原的嵌合抗原受体（CAR）T 细胞是一种有前景的策略，临床试验结果令人鼓舞。然而，针对利妥昔单抗难治/复发（R/R）B 细胞非霍奇金淋巴瘤（B-NHL）患者，尤其是近期接受过利妥昔单抗治疗的患者，CD20 CAR-T 细胞的疗效和安全性研究仍很少。本前瞻性研究旨在评估既往接受利妥昔单抗治疗的 R/R B-NHL 患者接受 CD20 CAR-T 细胞治疗的疗效和毒性。
方法
作者开展一项前瞻性、单中心 I 期研究，评估 CD20 CAR-T 细胞在既往接受利妥昔单抗治疗的 R/R B-NHL 患者中的疗效和毒性（ChiCTR2000036350）。2017 年 11 月 21 日至 2021 年 12 月 1 日共纳入 15 例 R/R B-NHL 患者。
结果
所有入组患者均有应答，总缓解率为 100%；最佳疗效为 12 例（80%）完全缓解和 3 例（20%）部分缓解。中位随访时间为 12.4 个月。数据截止时，无进展生存期和总生存期中位数均尚未达到。无患者发生 4 级细胞因子释放综合征，仅 1 例患者发生免疫效应细胞相关神经毒性综合征。
结论
所有既往对利妥昔单抗治疗难治或复发的入组 B-NHL 患者均获得不同程度的临床应答，且毒性可耐受。值得注意的是，3 个月内接受过利妥昔单抗治疗的患者预后较差。
展开英文摘要原文
METHODS
The authors conducted a prospective, single-center phase I study on the effectiveness and toxicity of CD20 CAR T cells in rituximab-treated R/R B-NHL patients (no. ChiCTR2000036350). A total of 15 patients with R/R B-NHL were enrolled between November 21, 2017, and December 1, 2021.
RESULTS
An overall response rate of 100% was shown in enrolled patients, with 12 (80%) achieving complete remission and three (20%) achieving partial remission for the best response. The median follow-up time was 12.4 months. Progression-free survival and overall survival were not yet reached by the data cutoff day. No patient developed grade 4 cytokine release syndrome, and only one patient had immune effector cell-associated neurotoxicity syndrome.
CONCLUSIONS
All enrolled B-NHL patients who were previously R/R to rituximab achieved different degrees of clinical response with tolerable toxicities. Notably, patients who had received rituximab within 3 months had a poorer prognosis.
论文信息
- 作者
- Cheng Q、Tan J、Liu R、Kang L、Zhang Y、Wang E、Li Y、Zhang J
- 第一作者单位
- Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, China.China
- 通讯作者单位
- Department of Hematology, Third Xiangya Hospital of Central South University, Changsha, China. Electronic address: lixiner1975@163.com.China
- 文献类型
- I 期临床试验 · 非美国政府资助研究
- 期刊
- Cytotherapy2022 Oct
- 原文标识
- PubMed 35691818 · DOI 10.1016/j.jcyt.2022.05.001